Combination of THC and CBD Significantly Reduced Agitation in People with Late-Stage Dementia
Researchers presented results from the LiBBY clinical trial, which evaluated a medical formulation of THC and CBD in hospice-eligible patients with Alzheimer’s disease and other forms of dementia experiencing agitation. Participants who received the THC/CBD treatment showed lower agitation scores compared to those receiving a placebo, with improvements observed in both two and 12 weeks. Researchers also reported comparable rates of adverse events between the treatment and placebo groups, and sustained reductions in agitation were observed among participants who continued treatment through 24 weeks.
Read the full news release from Georgetown University by Karen Teber by clicking here.